Biogen Inc. (SNSE:BIIB)

Market Cap	24.55T
Revenue (ttm)	9.68T
Net Income (ttm)	1.55T
Shares Out	n/a
EPS (ttm)	10,553.51
PE Ratio	15.87
Forward PE	13.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	3
Open	n/a
Previous Close	181.06
Day's Range	n/a
52-Week Range	120.74 - 245.00
Beta	n/a
RSI	99.96
Earnings Date	Feb 12, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Santiago Stock Exchange
• Ticker Symbol: BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD